Kornimate/medical-research-clean huggingface dataset:
sbrt combined with pd-1 antibody and chemotherapy in oligometastatic nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this is a multicenter, single-arm, phase ii clinical trial. the purpose of this study is to evaluate the efficacy and adverse effect of sbrt combined with programmed death 1 (pd-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.


Eligibility criteria:
inclusion criteria: * diagnosed as metastatic npc with no more than 3 metastatic lesions; * histopathological diagnosis of npc; * ecog 0-1 point; * has not received prior systemic treatment, such as radiotherapy, chemotherapy, immunotherapy or biotherapy; * no contraindications to immunotherapy and chemoradiotherapy; * every metastatic lesions could receive sbrt safely; * subject must have a measurable target lesion based on recist v1.1; * adequate marrow function: wbc count ≥ 3×10e9/l, ne count ≥ 1.5×10e9/l, hgb ≥ 90g/l, plt count ≥ 100×10e9/l; * adequate liver function: alt/ast ≤ 2.5×uln, tbil ≤ 2.0×uln; * adequate renal function: bun/cre ≤ 1.5×uln or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula); * take effective contraceptions during and three months after treatment; * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * allergic to monoclonal antibodies, any pd-1 antibody components, gemcitabine and cisplatin; * unexplained fever \> 38.5 ℃, except for tumor fever; * have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); * have a known history of human immunodeficiency virus (hiv), active hepatitis b (hbv-dna ≥10e3copiers/ml) or hepatitis c virus (hcv) antibody positive; * have previously treated with pd-1 antibody or other immunotherapy for pd-1/pd-l1 pathway; * have new york heart association (nyha) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; have known allergy to large molecule protein products or any compound of study therapy; * pregnant or breastfeeding; * prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma; * have received a live vaccine within 30 days of planned start of study therapy has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial; * any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.

Keywords: sbrt pd-1 antibody chemotherapy efficacy safety oligometastasis
study of the cell response in the tear film after overnight contact lens wear

Conditions: White Blood Cells

Summary: the purpose of this study was to count and analyze the white blood cells in tear samples collected from study participants following sleep. the results from contact lens wearers were compared with the results from non-contact lens wearers.

the objective of the study was to determine and compare the relative oxidative response of polymorphonuclear neutrophils (pmns), the relative cell adhesion response of pmns, and the leukocyte population in tear samples collected from contact lens wearers and non-contact lens wearers. tear samples were collected via a binocular eye-wash. the samples were processed, and a cell count was performed using a hemacytometer. flow cytometry was used to determine the expression of different pmn cell markers before and after stimulation with bacterial lipopolysaccharide (lps).

Eligibility criteria:
inclusion criteria: * 17 years of age or older. * ocular examination in the last two years. * has up-to-date spectacles. * falls into one of the following three categories: * adapted wearer of lotrafilcon a contact lenses * adapted wearer of lotrafilcon b contact lenses * does not wear contact lenses * other protocol-defined inclusion criteria may apply. exclusion criteria: * ocular disease * systemic or topical medications that may affect ocular health. * known sensitivity to diagnostic pharmaceuticals used in study. * uses artificial tears and/or rewetting drops. * wears contact lenses on an overnight basis for more than one night per week. * other protocol-defined exclusion criteria may apply.
personalized physical back training program to improve physical functioning in people with non-specific low back pain

Conditions: Exercise Therapy; Low Back Pain

Summary: personalized medicine and individualized therapeutic approaches are prominent in current research. but are these approaches also effective for treating non-specific low back pain (nslbp)? nslbp is one of the most common musculoskeletal issues, which can impair physical well-being, reduce the quality of life, and limit physical functioning. additionally, it contributes to substantial direct and indirect healthcare costs, such as frequent doctor visits and work absences. despite nslbp being a significant burden for both individuals and society, effective alleviation methods remain unclear. the investigators' research project therefore aims to investigate whether personalized therapy, specifically a personalized physical back training program, can effectively address nslbp. within the context of nslbp, the investigators' specific aim is to improve physical functioning as this outcome is considered relevant from all perspectives, including those of patients, clinical professionals, researchers, and guidelines.


Eligibility criteria:
inclusion criteria: * access to the university sports of the lucerne universities (i.e., students, employees, alumni, subscribers) * nslbp for at least 6 weeks * activity limiting nslbp (at least one activity with a psfs score of ≤ 50/100 on a scale from 0 = unable to perform due to nslbp to 100 = able to perform at the same level as before nslbp) * age between 18 and 65 years * understand the german language * willing to participate in the study * written informed consent exclusion criteria: * specific lbp * red flags associated with any serious pathology or specific lbp, * being on a waiting list for or less than 12 months post any surgery of the lower back * pregnancy or given birth within the last 12 months * diagnosed central neurological disease * not allowed to exercise * participant in the feasibility study * expecting to be absent for more than 2 weeks during the intervention period

Keywords: physical functioning exercise
study of malnutrition in primary school children

Conditions: Malnutrition, Child

Summary: study of malnutrition in primary school age children aim to asses the prevelance of malnutrition amoung the children in this age group and also ldintified the factors that affect in malnutrition between the children and the study will done in two primary school one present in rural area and another in urban area to compare the factor and the result that affect in both two different area

study of malnutrition in primary school age children aim to asses the prevelance of malnutrition amoung the children in this age group and also ldintified the factors that affect in malnutrition between the children and the study will done in two primary school one present in rural area and another in urban area to compare the factor and the result that affect in both two different area investigators in this study will use anthropometric measurment to asses wheight and height and bmi and also collect sociodemographic data from participant for ex father and mother education and age ,sex,place of residence,father and mother jop, mean income. and also collect data about hygine lnformation for ex safe and cleen drink water , presence of toilet ,wash hand before and after eating and cooking ,clean nail . other data will be collected from participant about dietary habits for ex how many times eating meat, paultary ,fish in week and how many times eating vegetable,fruits ege milk in day . this all data will be analysed by use the proper statical analysis system and finally the results will obtained

Eligibility criteria:
inclusion criteria: * healthy children who agree the participate in study (6-12) years old . * both sexes. exclusion criteria: * children below sex years or above 12 years . * children not in primary school . * children who refuse participate in study.

Keywords: malnutrition
a randomised multi-centre study to compare the long-term performance of the future hip to 3 other implants in primary total hip replacement

Conditions: Osteoarthritis; Post-traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis; Perthes Disease

Summary: this post-market clinical follow-up study was designed to compare hip replacement outcomes of the european hip against 3 controls (omniflex, zweymuller, and spotorno), however omniflex did not end up being used. the first patient had surgery on february 18, 2000 and the final patient had surgery on september 2, 2005. there were 317 subjects consented but only 301 had hip replacement surgery (subjects received: 220 european hips, 33 zweymuller, and 48 spotorno). the study took place at three sites. each site used their standard device as the control. the austrian site enrolled 69 european hips and 33 zweymuller hips. 92 european hips and 48 spotorno hips were enrolled in germany. finally, the site in italy enrolled 59 european hips. although the study protocol intended collecting dexa and rsa outcomes, the data collected by the sites did not include these outcomes.


Eligibility criteria:
inclusion criteria: i) administrative - the subject is able to understand the study, is willing to give voluntary, written, informed consent, will co-operate with assessment procedures and is geographically able to comply with the post-operative follow-up regime. ii) age - the subject's age is between 18 and 75 years inclusive. iii) sex - male or female subjects may be recruited to the study. iv) diagnosis -subjects must be undergoing primary thr surgery for non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis, post-traumatic arthritis, fractured neck of femur and non-union of fractured neck of femur, sufe or perthes disease. v) suitability - subjects who in the opinion of the investigator are considered to be suitable for treatment with the devices involved in the study. exclusion criteria: i) subjects undergoing revision procedure to the operative hip. ii) subjects who have had a previous femoral osteotomy to the operative hip. iii) subjects who have a history of active sepsis in the joint. iv) subjects who have been diagnosed with primary or secondary carcinomas in the last five years (excluding basal cell carcinoma or cervical carcinoma). v) subjects with any condition which may, in the opinion of the investigator, interfere with the total hip replacement's survival or outcome, e.g. paget's disease, charcot's disease. vi) subjects with psycho-social disorders which, in the opinion of the investigator would limit rehabilitation. vii) subject's whose weight is \> 100kg. viii) subjects with femoral head necrosis on the non-operated side (rsa and dexa subjects only). ix) subjects who have a fracture of the femur \> 6 months old (rsa and dexa subjects only). x) subjects diagnosed as having ankylosing spondylitis (rsa and dexa subjects only) xi) subjects with a known history of poor compliance to medical treatment.

Keywords: hip cementless
outcomes and risk factors of different treatment strategies for neuro-co-cardiological diseases and post-cardiac surgery cerebrovascular diseases

Conditions: Neuro-co-cardiological Diseases; Post-cardiac Surgery Cerebrovascular Diseases; Vascular Lesion

Summary: the objective of this observational cohort study is to evaluate the clinical outcomes of various treatment strategies for cerebrovascular and cardiovascular diseases. furthermore, it aims to investigate the factors that influence adverse outcomes from these treatments.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases. exclusion criteria: 1. the expected survival is less than 1 years; 2. simultaneously merge other serious diseases;

Keywords: neuro-co-cardiological diseases post-cardiac surgery cerebrovascular diseases simultaneous treatment staged treatment conservative treatment
3dpct combined with ct guided risi in the treatment of thoracic malignant tumors

Conditions: Radioactive Iodine-125 Brachytherapy; Thoracic Cancer; 3D Printing Coplanar Template; Nuclear Radiation Effects

Summary: the main technical difficulties in radioactive iodine-125 seed implantation (risi) lie in the complexity of operation and the control of operation quality. the current data shows that under the combined guidance of 3d-printing template and ct, the accuracy of risi has been significantly improved, and the actual target dose could meet the design requirements of preoperative plan. at present, 3d printing templates (3dpt) are divided into non-coplanar templates (3dpnct) and coplanar templates (3dpct). in clinical practice, due to the complex technical requirements, high production cost and long printing time of 3dpnct, a considerable number of patients can also complete the treatment with 3dpct. moreover, compared with 3dpnct, 3dpct has the advantages of accurate needle path control, fast needle path adjustment, convenient for intraoperative real-time optimization, without waiting for printing time, easy for doctors to master, lower cost than 3dpnct, and easy to carry out at the grass-roots level. therefore, this study intends to explore 3dpct technology to further clarify: (1) the accuracy of 3dpct assisted ct guided risi in the treatment of thoracic malignant tumors; (2) the short-term efficacy and toxicity of 3dpct assisted ct guided risi in the treatment of thoracic malignant tumors.


Eligibility criteria:
inclusion criteria: * pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm. * there is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment. * no bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment. * no serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found. * there is a suitable puncture path, and the therapeutic dose is expected to be achieved. * kps \> 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months. exclusion criteria: * severe impairment of lung function (such as fev1 \< 40% predicted value, fvc \< 50% predicted value, dlco \< 40% predicted value). * high risk of skin invasion and ulceration at the puncture site before treatment. * there is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor. * pregnant women, lactating women and mentally ill patients. * the patient with poor compliance and unable to complete the treatment. * other conditions of the researchers who think it is not suitable to participate in this clinical trial.
electroacupuncture for relieving pain in ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: background: ankylosing spondylitis imposes burdens on individuals and society that as costs 3 times higher than general population. conventional approaches for as have their limitation. previous studies demonstrated acupuncture has significant therapeutic effects for as in diminishing joint pain, enhancing functional disorders and modifying spinal deformity. although acupuncture is effective in relieving pain in as patients, the evidence is very limited due to methodological flaws. design this study will be a single-arm pilot study in patients with as. eligible subjects will receive electroacupuncture treatment twice per week for at least 6 weeks (12 sessions in total). the length of treatment can be extended to a maximum of 10 weeks (20 sessions in total) if participants request a prolonged treatment. the acupuncturist, who is a registered chinese medicine practitioner, of this trial will not participate in data collection and data entry. objective: to explore the treatment effect of electroacupuncture for relieving pain in ankylosing spondylitis. setting: hong kong participants: 20 subjects with a diagnosis of ankylosing spondylitis main measures: pain severity numerical rating scale (nrs), adverse events data analysis all data will be double-entered and checked for consistency before conducting the analysis. binomial test will be used to analyze the percentage of responders to treatment compared with a reference value of 10%. wilcoxon signed rank test will be used to compare the values of all continuous variables between baseline and post treatment. the population for safety analyses will include all subjects who receive at least one acupuncture treatment. adverse events will be coded using the who adverse reaction terminology dictionary. special attention will be given to those subjects who have discontinued treatment due to adverse events or who experience serious adverse events.


Eligibility criteria:
inclusion criteria: 1. with a diagnosis of as and fulfilled either asas criteria or modified new york criteria, 2. bath ankylosing spondylitis disease activity index, basdai ≥4, 3. currently taking analgesic or nsaids for pain control, 4. spinal pain assessment score≥4 on a numerical rating scale (nrs; 0-10 scale) exclusion criteria: 1. having active skin lesion or open wound over the needle placement areas; 2. having heart disease, bleeding disorder or taking anticoagulant drugs 3. have previous acupuncture experience 12 months before the baseline, 4. are pregnant, breast-feeding or of childbearing potential but not using adequate contraception; 5. having psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis or reactive arthritis; 6. having unstable medical condition such as liver and/or kidney failure or cancers.; 7. concurrently taking or injecting steroid.
the effects of dietary palmitic acid triacylglyceride position on bone strength parameters in infants

Conditions: Personal Satisfaction

Summary: the purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters.

infattm is an advanced basic-fat ingredient, which mimics the fat composition and properties of human milk fat and enabling optimal intake of the essential calcium and energy (in the form of fatty acids) and easy digestion. these benefits are the results of a unique fatty acid composition on the glycerol backbone, which ensure high level of palmitic acid at the middle (sn-2) position. the purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters, anthropometric parameters, wellbeing and stool characteristics in term and preterm infants.

Eligibility criteria:
inclusion criteria: 1. gestational age above 32 weeks as determined by menstrual history and corroborated by prenatal us and/or physical examination. 2. birth weight appropriate for gestational age (aga) using current cdc growth charts, and above 1750gr. 3. the mother had unequivocally decided not to breast-feed (in formula groups) or the mother had decided to breast feed (in human breast milk group). 4. the infant is apparently healthy. 5. parental/ legal guardian written inform consent 6. apgar after 5 minutes \>7 7. enrolled within their first 14 days of life for term infants and first month of life for preterm infants 8. at enrollment: clinical stability and acceptable weight gain exclusion criteria: 1. the infant suffer from a congenital or chromosomal disorder (cystic fibrosis, tracheomalacia, tracheoesophageal fistula, major congenital heart disease, down-syndrome) 2. the infant suffer from neonatal morbidities: * bronchopulmonary dysplasia (bpd) * intraventricular hemorrhage3-4 (ivh) * necrotizing enterocolitis (nec) 3. laboratory or clinical sings of osteopenia 4. the infant suffers from any suspected or known metabolic or physical limitations interfering with feeding or normal metabolism (require a special formula) 5. the mother suffers from any disease or disability that may interfere with her ability to take care of her infant 6. any other reason that, in the opinion of the investigator, prevents the subject from participating in the study

Keywords: term infants preterm infants bone strength speed of sound (sos) ultrasound
comparison of efficacy, safety and costs of recombinant fviii products between on-demand and secondary prophylaxis groups in haemophilia a patients

Conditions: Hemophilia

Summary: the project is an observational, multi-central, prospective, non-interventional and open-label data collection study on secondary prophylaxis with recombinant fviii products in adolescents and adults with severe hemophilia a (fviii \< 1%). it will be a controlled observation of patients on secondary prophylaxis versus on-demand treatment regimen. patients will be enrolled preferably on a 1:1 basis with regards to prophylaxis and on-demand treatment. the patient enrollment period will be 2 years with a follow-up (observation period) of 2 years for each patient. based on the primary effectiveness parameters (joint bleeds and overall bleeds per year) an observation period of 2 years is considered sufficient although it has to be admitted that it is rather short to assess the progression of orthopedic status. previously treated prophylaxis patients with at least 50 exposure days and patients with continuing prophylaxis treatment will be included.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * severe hemophilia a (fviii\<1%) diagnosis * prior treatment or ongoing treatment with on-demand or prophylaxis regimens according to turkish guidelines and requirements * previously treated patients with at least \>50 exposure days * written informed consent signed by patient/legal representative exclusion criteria: * currently on immune tolerance treatment * platelet count \< 75,000/mm3 * participation in another study * existence of inhibitors in the past and in the last currently available blood sample prior to study start (bethesda titer \< 0.6 bu/ml) * existence of inhibitor history in family members who also are diagnosed with hemophilia a * having been on primary prophylaxis as defined in the introduction * participation in another study

Keywords: hemophilia turkey observational adult